🇪🇺 Cross-Over Boceprevir Treatment in European Union

EMA authorised Cross-Over Boceprevir Treatment on 18 July 2011

Marketing authorisation

EMA — authorised 18 July 2011

  • Application: EMEA/H/C/002332
  • Marketing authorisation holder: Merck Sharp Dohme Ltd
  • Local brand name: Victrelis
  • Indication: Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
  • Status: withdrawn

Read official source →

Cross-Over Boceprevir Treatment in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Virology / Hepatology approved in European Union

Frequently asked questions

Is Cross-Over Boceprevir Treatment approved in European Union?

Yes. EMA authorised it on 18 July 2011.

Who is the marketing authorisation holder for Cross-Over Boceprevir Treatment in European Union?

Merck Sharp Dohme Ltd holds the EU marketing authorisation.